Biotechnology Entrepreneurship. Can Unicorns Exist in Russia?
The pandemic has had a huge impact on transformation of biotechnological innovations. Russian scientists have already demonstrated their prowess to the global scientific and business communities when the first ever coronavirus vaccine Sputnik V was registered in August 2020. To become a ‘unicorn’ in biotechnology, a startup needs to offer the market an entirely new product or present a significant transformation of an existing one. In global practice, it is becoming common practice when biotechnological innovations are created in cooperation: science and market go for maximum partnership. Lately, large industrial corporations in Russia work together with biotechnology startups to create incubation and acceleration programmes for start-ups, tailored to the needs of the market. Using the opportunities provided by these accelerators, young scientists, guided by the industry, hone their entrepreneurial skills, develop innovative technologies under the auspices of medical clinics, learn to attract investment, and receive mentoring support from the experts.
● How can the existing start-ups be sustained in Russia, new ones grown, and what is needed to take Russian innovations to the international arena?
● What conditions need to be created for inflow of investment to biotechnological startups?
● What should the integration of government, universities, labs, and industrial partners be like?
● What do innovation startups focus on now?
Pekka Viljakainen, Advisor to the Chairman of the Board of Directors, Skolkovo Foundation; Chairman, Aii Capital
Arkady Dvorkovich, Chairman, Skolkovo Foundation
Natalia Komarova, General Director, Rusatom Healthcare
Igor Korobko, Head of Science and Innovative Development of Health Department, Ministry of Health of the Russian Federation (online)
Dmitry Kudlay, General Director, Generium
Sophie Park, Chief Strategy Officer, Bayer G4A (online)
Robert Scott, Head of Product & Portfolio, Novartis Biome (online)
Evgeny Shlyakhto, Director General, Almazov National Medical Research Centre; President, All-Russian Non-Governmental Organization "Russian Society of Cardiology"
Front row participants
Noor Jandali, Analyst, Droobi Health, Qatar
Sergei Sorokin, CEO, Botkin.AI
Vadim Tarasov, Director, Institute of Translational Medicine and Biotechnology